The tweet was deleted by the author.
But we saved everything 🙂.
Camp4 Therapeutics Corp has announced its commitment to advancing potential therapies targeting the underlying biology of rare and neurological diseases.
The company highlighted the ongoing unmet needs affecting individuals and families facing rare conditions such as SYNGAP1, in recognition of Rare Disease Day. Camp4 Therapeutics Corp aims to address the substantial gaps in available treatments by focusing on innovative approaches in therapeutic development. The initiative underscores both the urgent demand for novel solutions and the biotech sector’s increasing investment in rare disease research.